{'fraction_non_alphanumeric': 0.03286978508217446, 'fraction_numerical': 0.022756005056890013, 'mean_word_length': 4.91044776119403, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Potential of growth hormone-releasing hormone antagonists (JV-1-36 and JV-1-42) for the treatment of brain tumours

Malignant glioblastoma is the most common type of primary brain tumour in adults. Current therapies are palliative and prolong quality survival. JV-1-36 and JV-1-42 are examples of peptide growth hormone-releasing hormone antagonists. JV-1-36 has been shown to decrease the size of subcutaneous human glioblastoma tumours in nude mice, and to extend the survival of nude mice implanted orthotopically with glioblastoma. JV-1-42 has been shown to cross the blood–brain barrier very effectively in mice; thus, the JV series of growth hormone-releasing hormone antagonists are showing promise for glioblastoma and should be further developed for the treatment of this condition.